Johnson & Johnson's Tremfya shows fistula remission at 48 weeks in Crohn's

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. COF
6. SMCI
7. RTX
8. TSLA
9. CRWV
10. S

Go back to Johnson & Johnson's Tremfya shows fistula remission at 48 weeks in Crohn's

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

October 19, 2026 8:00 AM EDT

TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn's disease

SPRING HOUSE, Pa., Oct. 19, 2026 /PRNewswire/ -- Johnson & Johnson... More